A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson, Jan H. M. Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1619-1628
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number6
DOIs
Publication statusPublished - Dec 2011

Keywords

  • MEK 1/2 inhibitor
  • Selumetinib
  • Phase I
  • Food effect

Cite this